Global Vendor Neutral Archive (VNA) Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Vendor Neutral Archive (VNA) Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Vendor Neutral Archive Vna Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 3,335.13 Million
Diagram Market Size (Forecast Year)
USD 4,945.12 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Mylan
  • Teva Pharmaceutical Industries

Global Vendor Neutral Archive (VNA) Market, By Delivery Mode (On-Premise VNA, Hybrid VNA, Fully Cloud-Hosted VNA), Procurement Mode (Departmental VNA, Multi-Departmental VNA, Multi-Site VNA), Imaging Modality (Angiography, Mammography, Computed Tomography, Digital Fluoroscopy, Digital Radiography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound, Other), Usage Model (Single Department, Multiple Departments, Multiple Sites), Player Type (PACS, Independent Software, Infrastructure) – Industry Trends and Forecast to 2030.

Vendor Neutral Archive (VNA) Market

Vendor Neutral Archive (VNA) Market Analysis and Size

The global vendor neutral archive market is anticipated to grow significantly over the forecast period to its inherent advantages in vendor flexibility and accessibility over the picture archiving and communication system (PACS). PACS can handle pictures from positron emission tomography (PET), endoscopy (ES), ultrasound, magnetic resonance, radiography, mammography, and other medical imaging equipment.

Data Bridge Market Research analyses that the global vendor neutral archive (VNA) market which was USD 3,335.132 million in 2022, is expected to reach USD 4,945.12 million by 2030, and is expected to undergo a CAGR of 5.13% during the forecast period of 2023 to 2030. “On-Premise VNA” dominates the delivery mode segment of the global vendor neutral archive (VNA) market due to digitalization of healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vendor Neutral Archive (VNA) Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Delivery Mode (On-Premise VNA, Hybrid VNA, Fully Cloud-Hosted VNA), Procurement Mode (Departmental VNA, Multi-Departmental VNA, Multi-Site VNA), Imaging Modality (Angiography, Mammography, Computed Tomography, Digital Fluoroscopy, Digital Radiography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound, Other), Usage Model (Single Department, Multiple Departments, Multiple Sites), Player Type (PACS, Independent Software, Infrastructure)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.),  F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada)

Market Opportunities

  • Cloud-based VNAs
  • Global expansion of healthcare systems
  • Research and development

Market Definition

The vendor-neutral archive (VNA) facilitates the acquisition, administration, and storage of image while facilitating communication between several PACS vendors. Throughout the forecast period, the consolidation of patient data by combining VNA with electronic health records (EHR) and their subsequent introduction is expected to provide opportunities for market expansion. The vendor-neutral archive (VNA) market is still in its early stage and show significant growth potential. In order to fabricate best-in-class solutions throughout the healthcare sector, the industry is marked by numerous inter-firm alliances.

Global Vendor Neutral Archive (VNA) Market Dynamics

Drivers

  • Digitalization of Healthcare

The ongoing digitalization of healthcare is a powerful force driving VNA adoption. The shift from paper-based medical records to digital formats is seen as essential for enhancing the efficiency and accessibility of patient data. This transformation extends to medical imaging and diagnostic records, which increasingly rely on digital storage and management. As healthcare providers strive to modernize their practices, VNAs emerge as critical tools for handling digital health data effectively.

  • Interoperability and Data Exchange Needs

The need for interoperability and data exchange is a pressing driver for VNAs. Healthcare systems often rely on diverse IT platforms and applications, including picture archiving and communication systems (PACS) and electronic health records (EHRs). These systems must seamlessly share data to provide comprehensive patient care. VNAs bridge the interoperability gap by acting as central repositories, ensuring that patient data can be accessed and utilized across various healthcare settings.

  • Growing Medical Imaging Data

The exponential growth in medical imaging data is a significant driver for VNAs, particularly in radiology and imaging departments. The proliferation of imaging technologies such as X-rays, MRIs, and CT scans generates vast amounts of digital image data. VNAs are uniquely equipped to handle and store these large datasets efficiently, ensuring that critical medical images are readily accessible to healthcare professionals when needed.

Opportunities

  • Regulatory Requirements and Industry Standards

Regulatory requirements and industry standards play a crucial role in VNA adoption. Regulations such as the health insurance portability and accountability act (HIPAA) and standards such as the digital imaging and communications in medicine (DICOM) set stringent guidelines for data security, privacy, and interoperability in healthcare. Compliance with these regulations is non-negotiable, and VNAs provide a means to ensure that patient data adheres to these standards.

  • Cloud-Based VNAs

The adoption of cloud-based VNAs presents an opportunity for healthcare organizations to mitigate some of the implementation challenges. Cloud solutions offer scalability, reducing the need for extensive on-premises infrastructure. This approach can be cost-effective and provides flexibility, making VNAs accessible to facilities of varying sizes.

Restraints/Challenges

  • Cost and Implementation Challenges

The cost and implementation challenges associated with VNAs can be a significant barrier, particularly for smaller healthcare facilities. Deploying a VNA system often requires substantial financial investment, including hardware, software, and IT infrastructure upgrades. In addition, the technical expertise required for implementation can pose challenges for organizations with limited resources.

  • Legacy Systems and Vendor Lock-In

Many healthcare organizations operate with legacy PACS and EHR systems, which can create complexities during the migration to VNAs. Vendor lock-in and integration difficulties can hinder the transition. Organizations must carefully plan and execute migration strategies to avoid disruptions in patient care.

This global vendor neutral archive (VNA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vendor neutral archive (VNA) market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In October 2021, Intelerad Medical Systems, global leader among medical image management solutions, announced its acquisition of Ambra health, a cloud-based medical image management group maker. The merged platform will provide physicians, patients, and researchers with a superior cloud solution for reading, storing, and sharing diagnostic imaging by combining two KLAS Research category leaders

Global Vendor Neutral Archive (VNA) Market Scope

The global vendor neutral archive (VNA) market is segmented on the basis of delivery mode, procurement mode, imaging modality, usage model, and player type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Delivery Mode

  • On-Premise VNA
  • Hybrid VNA
  • Fully Cloud-Hosted VNA

Procurement Mode

  • Departmental VNA
  • Multi-Departmental VNA
  • Multi-Site VNA

Imaging Modality

  • Angiography
  • Mammography
  • Computed Tomography
  • Digital Fluoroscopy
  • Digital Radiography
  • Magnetic Resonance Imaging
  • Nuclear Imaging, Ultrasound
  • Other

Usage Model

  • Single Department
  • Multiple Departments
  • Multiple Sites

Player Type

  • PACS
  • Independent Software
  • Infrastructure

Global Vendor Neutral Archive (VNA) Market Regional Analysis/Insights

The global vendor neutral archive (VNA) market is analyzed and market size insights and trends are provided by delivery mode, procurement mode, imaging modality, usage model, and player type as referenced above.

The countries covered in the global vendor neutral archive (VNA) market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global vendor neutral archive (VNA) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030, due to the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global vendor neutral archive (VNA) market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global vendor neutral archive (VNA) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global vendor neutral archive (VNA) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global vendor neutral archive (VNA) market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Global Vendor Neutral Archive (VNA) Market Share Analysis

The global vendor neutral archive (VNA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to global vendor neutral archive (VNA) market.

Some of the major players operating in the global vendor neutral archive (VNA) market are:

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Merck & Co., Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Baxter (U.S.)
  • Bayer AG (Germany)
  • Eli Lilly and Company (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Allergan (Ireland)
  • AbbVie Inc. (U.S.)
  • Abbott (U.S.)
  • Bausch Health Companies Inc. (Canada)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Global Vendor Neutral Archive (VNA) Market, By Delivery Mode (On-Premise VNA, Hybrid VNA, Fully Cloud-Hosted VNA), Procurement Mode (Departmental VNA, Multi-Departmental VNA, Multi-Site VNA), Imaging Modality (Angiography, Mammography, Computed Tomography, Digital Fluoroscopy, Digital Radiography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound, Other), Usage Model (Single Department, Multiple Departments, Multiple Sites), Player Type (PACS, Independent Software, Infrastructure) – Industry Trends and Forecast to 2030. .
The Global Vendor Neutral Archive Vna Market size was valued at USD 3335.13 USD Million in 2022.
The Global Vendor Neutral Archive Vna Market is projected to grow at a CAGR of 5.13% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, GlaxoSmithKline, Novartis, Mylan, Teva Pharmaceutical Industries, Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co., F. Hoffmann-La Roche, Baxter, Bayer, Eli Lilly and Company, Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, Allergan, AbbVie, Abbott, Bausch Health Companies.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.